Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Neuronetics Stock Performance
NASDAQ:STIM traded down $0.01 during trading on Friday, reaching $4.46. 120,343 shares of the company's stock were exchanged, compared to its average volume of 422,742. The company has a debt-to-equity ratio of 0.46, a current ratio of 5.02 and a quick ratio of 4.64. The business has a 50 day moving average price of $3.67 and a 200-day moving average price of $3.20. The stock has a market capitalization of $120.52 million, a P/E ratio of -3.19 and a beta of 2.09. Neuronetics has a fifty-two week low of $1.98 and a fifty-two week high of $8.88.
Neuronetics (NASDAQ:STIM - Get Rating) last posted its earnings results on Thursday, May 12th. The company reported ($0.41) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.41). Neuronetics had a negative return on equity of 46.12% and a negative net margin of 62.44%. The business had revenue of $14.18 million for the quarter, compared to analyst estimates of $13.20 million. During the same period in the previous year, the firm earned ($0.31) EPS. Sell-side analysts forecast that Neuronetics will post -1.65 earnings per share for the current fiscal year.
Insider Buying and Selling at Neuronetics
In related news, major shareholder Cannell Capital Llc acquired 15,369 shares of the firm's stock in a transaction on Friday, May 20th. The shares were purchased at an average cost of $2.41 per share, for a total transaction of $37,039.29. Following the completion of the acquisition, the insider now directly owns 3,393,063 shares in the company, valued at $8,177,281.83. The purchase was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Keith J. Sullivan sold 63,466 shares of the stock in a transaction that occurred on Monday, July 18th. The stock was sold at an average price of $3.72, for a total transaction of $236,093.52. Following the transaction, the chief executive officer now owns 850,999 shares in the company, valued at $3,165,716.28. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Cannell Capital Llc purchased 15,369 shares of the company's stock in a transaction that occurred on Friday, May 20th. The shares were purchased at an average cost of $2.41 per share, with a total value of $37,039.29. Following the completion of the acquisition, the insider now owns 3,393,063 shares in the company, valued at approximately $8,177,281.83. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 110,632 shares of company stock valued at $275,932 and sold 79,533 shares valued at $293,135. Insiders own 5.20% of the company's stock.